TerSera Therapeutics LLC

Biotech

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 2 drugs with upcoming expirations

Activity

Recent Activity

Last 14 days

Jul 14, 2026

Approved for marketing

Margetuximab Expanded Access Program

Earlier

Apr 29, 2026TrialA Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

Mar 25, 2020TrialPhase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine

Mar 13, 2019TrialA Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer

Oct 25, 2017FDAVarubi — VARUBI

Jun 22, 2017TrialReal-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO

Feb 28, 2017FDAXermelo — XERMELO

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

7 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Varubi4 patentsApr 4, 2027 Xermelo2 patentsDec 11, 2027 VarubiAug 19, 2028 XermeloDec 19, 2028 Varubi2 patentsJan 18, 2029 Xermelo2 patentsFeb 27, 2031 VarubiJul 14, 2032

Regulatory

Regulatory Timeline

19891 event

FDADec 29

Zoladex — ZOLADEX

Application NDA019726 (NDA)

19961 event

FDAJan 11

Zoladex — ZOLADEX

Application NDA020578 (NDA)

20151 event

FDASep 1

Varubi — VARUBI

Application NDA206500 (NDA)

20172 events

FDAOct 25

Varubi — VARUBI

Application NDA208399 (NDA)

FDAFeb 28

Xermelo — XERMELO

Application NDA208794 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)